Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH
- Address
- In Der Schornau 23-25, Langendreer, 44892 Bochum, Germany
Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH - Comprehensive Oncology and Critical Care Research Center
The Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH stands as a leading academic medical center with extensive expertise in hematologic malignancies and neuro-oncology. The center demonstrates particular strength in conducting complex phase III trials for newly diagnosed cancers, with a focus on innovative therapeutic combinations and personalized medicine approaches. Their research portfolio encompasses a broad spectrum of adult oncology, including advanced trials in acute leukemias, lymphomas, and brain tumors, as well as critical care interventions.
- Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes - Multiple phase III trials evaluating novel agents including venetoclax, CPX-351, IDH inhibitors, and FLT3-targeted therapies in combination with chemotherapy
- Brain Tumor Research - Comprehensive glioma studies including glioblastoma, WHO grade 2/3 gliomas with 1p/19q co-deletion, and primary CNS lymphoma trials
- Lymphoma Therapeutics - Advanced Hodgkin lymphoma, aggressive B-cell lymphoma, and Philadelphia-positive acute lymphoblastic leukemia trials
- Solid Tumor Oncology and Critical Care - Investigations in hepatocellular carcinoma, rectal cancer, gastroesophageal adenocarcinoma, and sepsis management
The center's research approach emphasizes comparative effectiveness studies and treatment optimization, with particular attention to elderly patient populations and those ineligible for intensive chemotherapy. Their involvement in multiple myeloma maintenance strategies, transplant rejection prophylaxis in kidney transplant recipients, and novel immunotherapy combinations demonstrates a commitment to improving outcomes across diverse patient populations. The facility also conducts important metabolic disease research, including trials for non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease, alongside innovative critical care studies evaluating sedation strategies and adjunctive therapies for septic shock.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Cholangiocarcinoma treatment with radiofrequency ablation or photodynamic therapy | Universitaet Leipzig | Phase III | Recruiting | Oct 2022 | — |
IMP list
lock Showing 1 of 70 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 4 | Unknown | 2019-08-28 | 2025-12-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.